Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
出版年份 2012 全文链接
标题
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
作者
关键词
-
出版物
BLOOD
Volume 120, Issue 13, Pages 2650-2657
出版商
American Society of Hematology
发表日期
2012-08-12
DOI
10.1182/blood-2012-05-431825
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- (2012) C. Muller et al. BLOOD
- Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
- (2012) D. O. Persky et al. HAEMATOLOGICA
- Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
- (2012) U. Jager et al. HAEMATOLOGICA
- Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
- (2011) S. Veeramani et al. BLOOD
- Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
- (2011) G. Cartron et al. CLINICAL CANCER RESEARCH
- FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy
- (2011) V. PROCHAZKA et al. NEOPLASMA
- Effect of FCGR2A and FCGR3A variants on CLL outcome
- (2010) D. Dornan et al. BLOOD
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?
- (2010) Ph. Solal-Céligny et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
- (2009) Wen-Kai Weng et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma
- (2009) Wen-Kai Weng et al. LEUKEMIA & LYMPHOMA
- Thalidomide and rituximab in Waldenstrom macroglobulinemia
- (2008) S. P. Treon et al. BLOOD
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
- (2008) G. Salles et al. BLOOD
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies
- (2008) Julien Lejeune et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
- (2008) Robert Marcus et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now